echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Suoyuan Biosciences introduces global rights of Lingbei's Phase III clinical failure products in Alzheimer's disease

    Suoyuan Biosciences introduces global rights of Lingbei's Phase III clinical failure products in Alzheimer's disease

    • Last Update: 2021-08-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    On July 1, U.

    In February 2017, two other Alzheimer's (AD) phase III clinical trials of Idalopirdine, STARBEAM and STARBRIGHT, also announced failures

    However, in the phase II clinical trial, Idalopirdine performed well.

    Idalopirdine is an oral selective 5-HT6 receptor antagonist

    Suoyuan Biology published the prospectus on the Science and Technology Innovation Board on June 30, and plans to raise 1.

    The advantage of Suoyuan Bio's development of innovative drugs lies in the use of biomarker platform technology to find biomarkers that can predict drug efficacy in residual clinical samples

    Currently, the DB102 project of Suoyuan Biosciences is carrying out international multi-center phase III clinical trials for diffuse large B-cell lymphoma (DLBCL) and glioma (GBM)

    After the FDA approved the first Aβ monoclonal antibody Aducanumab on June 7, AD drugs became hot again.

    The FDA's change of AD drug review standards is the wind direction and inspiration.

    Idalopirdine has proven its safety and tolerability in the phase III clinical trials that have been carried out, but the efficacy of the three phase III clinical trials is not satisfactory.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.